



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/038,206	01/02/2002	Jasper Rine	UOCB118456	1317
26389	7590	04/06/2005	EXAMINER	
CHRISTENSEN, O'CONNOR, JOHNSON, KINDNESS, PLLC 1420 FIFTH AVENUE SUITE 2800 SEATTLE, WA 98101-2347			BRUSCA, JOHN S	
			ART UNIT	PAPER NUMBER
			1631	

DATE MAILED: 04/06/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.

10/038,206

Applicant(s)

RINE ET AL.

Examiner

John S. Brusca

Art Unit

1631

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 07 February 2005.
2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 38-85 is/are pending in the application.
4a) Of the above claim(s) _____ is/are withdrawn from consideration.
5) ☐ Claim(s) _____ is/are allowed.
6) ☒ Claim(s) 38-85 is/are rejected.
7) ☐ Claim(s) _____ is/are objected to.
8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
10) ☒ The drawing(s) filed on 02 January 2002 is/are: a) ☒ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) ☐ Notice of References Cited (PTO-892)
2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
3) ☐ Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date _____.
4) ☐ Interview Summary (PTO-413)
Paper No(s)/Mail Date _____.
5) ☐ Notice of Informal Patent Application (PTO-152)
6) ☐ Other: _____.

416

Art Unit: 1631

DETAILED ACTION

Claim Rejections - 35 USC § 101

1. 35 U.S.C. 101 reads as follows:

Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title.

2. Claim 69 is rejected under 35 U.S.C. 101 because the claimed invention is directed to non-statutory subject matter. Claim 69 is drawn to data in computer readable memory which is not patentable subject matter (see MPEP 2106).

3. Applicant's arguments filed 07 February 2005 have been fully considered but they are not persuasive. The applicants state that the claim has been amended to require that the claimed data in computer memory affects the functioning of a computer. However the amendment filed 07 February 2005 does not affect the claimed subject matter because the clause following "wherein" does not affect the content of the data in computer memory that is being claimed. It is further noted that the added clause states how a computer could use the data but does not address the position of the Office that the claimed data does not affect how a computer functions, rather the data merely is entered to a computer that is programmed to process data in a particular way and the claimed data does not affect how the computer processes the data.

Claim Rejections - 35 USC § 103

4. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

Art Unit: 1631

A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

5. This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(f) or (g) prior art under 35 U.S.C. 103(a).

6. Claims 38-53, 55-66, 68-83, and 85 are rejected under 35 U.S.C. 103(a) as being unpatentable over Gress et al. in view of Granelli-Piperno et al. in view of Fodor et al. (U.S. Patent No. 5,800,992).

The claims are drawn to a method of assay of the response of a living thing to a stimulus by use of an array of probes comprising a predetermined sequence of nucleotides to individual gene transcripts by comparing databases comprising results of hybridizations of labeled polynucleotides derived from cells either treated with different stimuli or unstimulated control cells, the database produced by the method, and methods of generating the database produced by

Art Unit: 1631

the method. The responses are measured by converting an output signal to an electrical signal and then converting the electrical signal to a value in a database. In some embodiments at least 50% of the gene transcripts of the cell are assayed, the cells are human cells, the probes consist of 24-240 nucleotides, and the database is computer implemented. In some embodiments the probes are in an X and Y coordinate grid. In some embodiments the method is repeated for different stimuli.

Gress et al. shows throughout, and especially on page 609 and figure 3 a general method of assaying patterns of transcription by use of labeled cDNA from mouse, and human cells by use of a cDNA X-Y coordinate grid array of probes. The array provides an optical signal of expression in an assayed human cell of individual genes in the cell. Gress et al. shows importing the resulting data via an electrical signal of a Phosphorimager to a computer implemented relational database on page 616. Gress et al. shows in the abstract that their high density array allows for the efficient assay of thousands of clones simultaneously. Gress et al. shows on page 612 that polyA control probes hybridize non-specifically to many array cDNA probes and that other cDNA probes in the array contained repetitive sequences that also caused non-specific hybridization. Gress et al. shows on page 616 that one strategy to avoid background non-specific hybridization is to use probes that lack polyA tails by use of modified primers. Gress et al. does not show subsection of assayed cells to different stimuli, or comparison of the transcriptional profile of cells that have received different stimuli, or assay of discrete portions of the complete number of genes of the cell, or use of probes with a predetermined sequence of nucleotides.

Art Unit: 1631

Granelli-Piperno et al. shows in figures 1-9 the effect of a variety of compounds on expression of genes of human cells. The tested compounds include cytokines, mitogens, cyclosporin A, and cycloheximide. The response is determined by the intensity of a film image on an autoradiograph. Granelli-Piperno et al. show that assay of expression of genes after treatment of cells with drugs allows a determination of the effect of the drug on individual gene expression and further serves to gain insights on the mechanism of action of the drug.

Fodor et al. shows throughout a method of making an array of polynucleotide probes of predetermined sequence by independent in situ stepwise synthesis of each oligonucleotide probe on the array. Fodor et al. shows in columns 32, lines 12-24 that their arrays may be used to map the location of a molecule on a chromosomal map. Fodor et al. shows in column 35 that their procedure may be used to assay the developmental stage cells from which the assayed sample is derived. In column 78-79, Fodor et al. shows that their method may be used to assay developmental stages of cells by assay of their mRNA content.

It would have been obvious to a person of ordinary skill in the art at the time the invention was made to modify the method of Gress et al. by assaying cells that have received treatments with different drugs according to the method of Granelli-Piperno et al. because Granelli-Piperno et al. shows that such an analysis serves to gain insights on the mechanism of action of the drug. It would have been further obvious to assay additional numbers of genes as desired to determine the effect of a drug on additional genes. Regarding the size of the probes, it would have been obvious to use portions of a cDNA probe of Gress et al. because Gress et al. shows that many array probes suffer from non-specific hybridization due to repetitive sequences

Art Unit: 1631

of polyA tracts and that the problem may be solved by use of shorter probes. It would have been further obvious to use an array of probes with a predetermined sequence as disclosed by Fodor et al. because Fodor et al. shows that such an array has the advantage of allowing the sequences detected in the sample to be mapped to a particular location of the genome of the organism sampled. Regarding the limitations of claims 71 and 72, it would be further obvious to one of skill in the art to perform simple mathematical comparisons of the levels in stimulated and control cells such as subtraction or division by the basal level to reveal the extent of change in the level of the assayed mRNA.

7. Claims 38, 49-51, 54, 56, 63-65, 67, 70, 80-82, and 84 are rejected under 35 U.S.C. 103(a) as being unpatentable over Gress et al. in view of Granelli-Piperno et al. in view of Fodor et al. as applied to claims 38-53, 55-66, 68-83, and 85 above, and further in view of Watson et al.

The claims are drawn to assays utilizing fungal cells.

Watson et al. shows on pages 573-575 that yeast cells contain genes that are regulated by stimuli such as metabolites.

It would have been obvious to a person of ordinary skill in the art at the time the invention was made to modify the method of Gress et al. in view of Granelli-Piperno et al. in view of Fodor et al. as applied to claims 38-53, 55-66, 68-83, and 85 above by using yeast gene probes and cells because Watson et al. shows that yeast cells have genes that are regulated by stimuli.

Art Unit: 1631

8. Applicant's arguments filed 07 February 2005 have been fully considered but they are not persuasive. The applicants state that Gress et al. does not need to sequence the cDNA hybridization targets, however Gress et al. does sequence selected clones to facilitate correlation of their results with other databases as shown in the abstract of Gress et al. It is therefore apparent that the prior art shows advantages and motivation for determining the sequence of elements of an array. Fodor et al. has been cited to show that the prior art details a method to create an array with predetermined sequences at each element, which has the advantage of obviating subsequent sequencing to characterize elements of interest determined by the hybridization experiment.

Conclusions

9. **THIS ACTION IS MADE FINAL.** Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Art Unit: 1631

10. Patent applicants with problems or questions regarding electronic images that can be viewed in the Patent Application Information Retrieval system (PAIR) can now contact the USPTO's Patent Electronic Business Center (Patent EBC) for assistance. Representatives are available to answer your questions daily from 6 am to midnight (EST). The toll free number is (866) 217-9197. When calling please have your application serial or patent number, the type of document you are having an image problem with, the number of pages and the specific nature of the problem. The Patent Electronic Business Center will notify applicants of the resolution of the problem within 5-7 business days. Applicants can also check PAIR to confirm that the problem has been corrected. The USPTO's Patent Electronic Business Center is a complete service center supporting all patent business on the Internet. The USPTO's PAIR system provides Internet-based access to patent application status and history information. It also enables applicants to view the scanned images of their own application file folder(s) as well as general patent information available to the public.


For all other customer support, please call the USPTO Call Center at (800) 786-9199.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to John S. Brusca whose telephone number is 571 272-0714. The examiner can normally be reached on M-F 8:30 AM - 5:00 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ardin Marschel, PhD. can be reached on 571 272-0718. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 1631

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

 4 April 2005
John S. Brusca

Primary Examiner

Art Unit 1631

jsb